

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: SOL Global Investments Corp. (the "Company" or "Issuer").

Trading Symbol: SOL

Number of Outstanding Listed Securities: 54,629,256

Date: December 4, 2019

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website. This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. **Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

On November 1, 2019, the Company announced its intention to commence a normal course issuer bid ("NCIB"), under which the Company may purchase up to 2,731,462 of the Company's common shares, representing approximately 5% of its issued and outstanding common shares. The NCIB will terminate on November 1, 2020. All common shares purchased under the NCIB will be purchased on the open market through the facilities of the Canadian Securities Exchange.

On November 13, 2019, the Company announced that it had filed an early warning report related to the purchase of common shares of Torque Esports Inc. (TSXV:GAME). The Issuer owned 2,014,000 Common Shares, representing approximately 12.5% of the issued and outstanding shares Common Shares on a non-diluted basis. On November 30, 2019, the Company announced that it sold 103,500 common shares in Torque Esports Corp. resulting in the Company becoming a beneficial holder of less than 10% of the issued and outstanding Common Shares.

On November 19, 2019, the Company announced its 40.7% owned portfolio company Heavenly Rx has entered into a memorandum of understanding ("MOU") with the US NASDAQ listed public company, Therapix Biosciences Ltd. (NASDAQ: TRPX), ("Therapix") a speciality clinical-stage pharmaceutical company with a portfolio of technologies and assets based on cannabinoid pharmaceuticals, pursuant to which Therapix and Heavenly Rx have agreed to pursue a business combination. Pursuant to the MOU, the parties will negotiate a definitive agreement for a business combination, constituting a reverse takeover of Therapix by Heavenly Rx.

The Company has applied to various regulatory and governmental authorities to change its year end from March 31 to November 30. If this change is approved, the Company will have an eight-month fiscal year ended November 30, 2019 and a twelve-month fiscal year ended November 30, 2020. The Company will file quarterly financial statements on the last day of February, May and August each year.

On April 23, 2019, the Company entered into a binding letter of intent with MCP Wellness, Inc. ("MCP Wellness") for US\$150,000,000. MCP Wellness is a special-purpose vehicle created to invest in Michigan cannabis operations. On November 27, 2019, the Company announced it was terminating this agreement. As part of the termination, MCP Wellness will repay the US\$12,500,000 advanced by the Company in installments over the next twelve months. During the repayment period, the Company and/or CannCure will have the option to acquire certain assets from MCP Wellness, convert any amounts due into stock in the Michigan operator, or complete the originally contemplated transaction on substantially similar terms. The companies also intend to negotiate a strategic licensing agreement whereby MCP Wellness would benefit from the cultivation techniques and standard operating procedures of CannCure.

On November 29, 2019, the Company announced that it had filed an early warning report related to its sale of 400,000 Common Shares of Frankly Inc. (TSX-V:TLK). The consideration received per Common Share under the Disposition was \$0.48, for total consideration received of \$189,352. Immediately following the completion of the Disposition, SOL beneficially owned 4,196,600 Common Shares, representing approximately 13.81% of the issued and outstanding shares Common Shares on a non-diluted basis.

- 2. Describe the acquisition of new customers or loss of customers.**
None noted.

3. **Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.**
None noted.
4. **Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**
None noted.
5. **Report on any labour disputes and resolutions of those disputes if applicable.**
None noted.
6. **Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**
None noted.
7. **Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**
None noted.
8. **Provide details of any securities issued and options or warrants granted.**
None noted.
9. **Provide details of any loans to or by Related Persons**
None noted.
10. **Provide details of any changes in directors, officers or committee members.**
None noted.
11. **Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**
None noted.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: December 4, 2019.

Peter Liabotis
Name of Director or Senior Officer
/s/ "Peter Liabotis"
Signature
CFO
Official Capacity

Issuer Details Name of Issuer SOL Global Investments Corp.	For Month End October 2019	Date of Report YY/MM/D 19/11/04
Issuer Address 5600-100 King St. West		
City/Province/Postal Code Toronto, ON, M5X 1C9	Issuer Fax No. ()	Issuer Telephone No. (212) 729-9208
Contact Name Peter Liabotis	Contact Position CFO	Contact Telephone No. (212) 729-9208
Contact Email Address info@solglobal.com	Web Site Address https://solglobal.com/	